Lisa P. Rumin

Subscribe to Lisa P. Rumin's Posts

Lisa P. Rumin focuses her practice on antitrust, regulatory and litigation matters. She assists clients across a variety of industries and has represented numerous clients in the healthcare, pharmaceutical, and biotechnology industries. Lisa advises clients on mergers and acquisitions, including obtaining clearance from the Federal Trade Commission (FTC) and Department of Justice (DOJ), as well as counsels clients on issues regarding antitrust compliance, pricing, and distribution. Read Lisa Rumin's full bio here.

Understanding How the New HSR Regime Impacts Your Business

By Jon B. Dubrow, Gregory E. Heltzer, Lisa P. Rumin, Ryan Tisch, Timothy (Ty) Carson and Reese Poncia on Nov 5, 2024
Posted In FTC Developments, Mergers & Acquisitions

During a recent webinar, Jon Dubrow, Greg Heltzer, Lisa Rumin, and Ryan Tisch provided a comprehensive introduction to the new Hart-Scott-Rodino (HSR) rules and their impact on the US premerger notification filing process. The program concluded with a Q&A moderated by Reese Poncia and featuring Ty Carson, a former Federal Trade Commission Premerger Notification Office lawyer, who shared his insider’s perspective from six years...

Continue Reading

New Premerger Notification Regime to Fundamentally Change M&A Strategy

By Jon B. Dubrow, Raymond A. Jacobsen, Jr., Lisa P. Rumin, Ryan Tisch, Noah Feldman Greene, Graham Hyman and Reese Poncia on Oct 16, 2024
Posted In FTC Developments, Mergers & Acquisitions

On October 10, 2024, the Federal Trade Commission issued new final rules governing the US premerger notification filing process. These rules – the first major overhaul to the Hart-Scott-Rodino (HSR) filing form in the nearly 50-year history of the HSR Act – will fundamentally alter the premerger notification process. While the rules omit some of...

Continue Reading

How Orange Book Antitrust Scrutiny Is Intensifying

By Elai Katz, Lisa P. Rumin and Betty Zhang on Aug 1, 2024
Posted In FTC Developments, Healthcare Antitrust, IP Antitrust, Monopolization/Abuse of Dominance

Pharmaceutical patent holders beware: Over the past year, antitrust enforcers have taken a more aggressive approach challenging Orange Book listings as an anticompetitive practice. According to the Federal Trade Commission, improperly listing patents in the Orange Book constitutes an unfair method of competition, among other violations. In this article, Elai Katz, Lisa Rumin and Betty...

Continue Reading

Effecting M&A Diligence When Competitors Are Involved

By Lisa P. Rumin, Gregory E. Heltzer and Matt Evola on May 31, 2024
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions

Increased scrutiny of the healthcare industry from antitrust agencies such as the Federal Trade Commission and US Department of Justice emphasize the necessity of compliance measures to mitigate antitrust risk that can negatively impact the closing of transactions. This article explores the critical role of clean team agreements (CTAs) in managing antitrust risks during the...

Continue Reading

Blocked JetBlue-Spirit Deal Illustrates New Antitrust Approach

By Lisa P. Rumin and Anthony S. Ferrara on Apr 15, 2024
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions

As reflected in the December 2023 merger guidelines, the Federal Trade Commission and the US Department of Justice have changed the way they think about out-of-market effects, i.e., competitive effects that arise outside the relevant market. In this Law360 article, Lisa Rumin and Anthony Ferrara unpack this new approach, which was prominently demonstrated during the...

Continue Reading

Heard at the 2024 Antitrust Law Section Spring Meeting: Part II

By Lisa P. Rumin, Anthony S. Ferrara, Reese Poncia, Noah Feldman Greene, Zachary Sproull, Han Cui, Graham Hyman, Glenna Siegel, Alex Grayson, Betty Zhang and Gregory E. Heltzer on Apr 12, 2024
Posted In Agriculture, DOJ Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions, Monopolization/Abuse of Dominance

The American Bar Association Antitrust Law Section’s annual Spring Meeting concluded on April 12. The annual Spring Meeting featured updates from federal, state and international antitrust enforcers and extensive discussion on priority antitrust issues affecting various industries. In this article, we highlight takeaways from the final two days of the Spring Meeting. Read more here.

Continue Reading

Heard at the 2024 Antitrust Law Section Spring Meeting: Part I

By Gregory E. Heltzer, Lisa P. Rumin, Reese Poncia, Anthony S. Ferrara, Claire Danberg, Glenna Siegel, Bailey K. Sanders, Betty Zhang and Alex Grayson on Apr 11, 2024
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions, Monopolization/Abuse of Dominance

The American Bar Association Antitrust Law Section’s annual Spring Meeting is underway in Washington, DC. The annual Spring Meeting features updates from federal, state and international antitrust enforcers and extensive discussion on priority antitrust issues affecting various industries. In this article, we highlight the key takeaways from the first portion of the Spring Meeting. Read...

Continue Reading

Google Moves to Dismiss Third Complaint Alleging Tying of Google Maps API Services

By Gregory E. Heltzer, Lisa P. Rumin and Glenna Siegel on Feb 28, 2024
Posted In DOJ Developments, Monopolization/Abuse of Dominance, Private Litigation

BACKGROUND Google LLC and Alphabet Inc. (Google) moved to dismiss a third successive complaint that alleged it tied the sales of Maps, Routes and Places application programming interface (API) services to one another. A basic tying claim involves a seller leveraging its market power in one product (the “tying” product) to force sales and gain...

Continue Reading

Year in Review: Criminal Enforcement by the DOJ Antitrust Division in 2023

By Nicole Castle, Lisa P. Rumin, Paul M. Thompson and Glenna Siegel on Feb 8, 2024
Posted In Cartel Enforcement, DOJ Developments, Mergers & Acquisitions

When it comes to antitrust criminal enforcement, 2023 will be remembered as the year when the US Department of Justice’s (DOJ) Antitrust Division redefined and tested the outer boundaries of its authority. This report looks back at the key events from the DOJ’s year in criminal antitrust enforcement. Here’s a glimpse of what’s inside: Despite...

Continue Reading